ABL1 (Phospho-Thr735) Antibody
- Known as:
- ABL1 (Phospho-Thr735) Antibody
- Catalog number:
- 11725
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- ABL1 (Phospho-Thr735) Antibody
Related genes to: ABL1 (Phospho-Thr735) Antibody
- Gene:
- ABL1 NIH gene
- Name:
- ABL proto-oncogene 1, non-receptor tyrosine kinase
- Previous symbol:
- ABL
- Synonyms:
- JTK7, c-ABL, p150
- Chromosome:
- 9q34.12
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: ABL1 (Phospho-Thr735) Antibody
Related articles to: ABL1 (Phospho-Thr735) Antibody
- Asciminib, a novel BCR::ABL1 inhibitor that functions by specifically targeting the myristoyl pocket, has shown superior efficacy and favorable safety and tolerability compared with adenosine triphosphate-competitive tyrosine kinase inhibitors (TKIs) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Flumatinib, a second-generation TKI available exclusively in China, does not have a head‑to‑head comparison with asciminib till date with asciminib. Therefore, this study aimed to conduct an anchored matching‑adjusted indirect comparison using data from the ASC4FIRST and FESTnd trials to fill this evidence gap. - Source: PubMed
Publication date: 2026/07/28
Wang YingHui YanZhang LiLi YanTang MengGao XueZhen BihongChoubey AbhayGupta SoniWei HuiLiu Bingcheng - Chronic myeloid leukemia (CML) with megakaryoblastic blast crisis (MKBC) as the initial manifestation is extremely rare, accounting for less than 3% of all CML cases. Philadelphia chromosome-positive acute myeloid leukemia, FAB M7 subtype (Ph+ AML-M7), is also known as Philadelphia chromosome-positive acute megakaryoblastic leukemia (Ph+ AMKL), representing a distinct and prognostically unfavorable category of AML. Morphologically and immunophenotypically, these two entities are nearly identical, posing significant diagnostic challenges. We describe a novel case of Ph+ leukemia with MKBC differentiation that appears most consistent with CML in blast phase (BP). Following treatment with a tyrosine kinase inhibitor (TKI) combined with induction and consolidation chemotherapy, the patient achieved complete remission (CR). Although hematopoietic stem cell transplantation (HSCT) was declined due to economic constraints, the patient has maintained deep molecular remission(MR5, BCR::ABL1 ≤ 0.001%)for 35 months to date. Through a systematic review of existing literature, this article elucidates key discriminative features between the two conditions and proposes a practical diagnostic and therapeutic framework to guide clinical decision-making. - Source: PubMed
Publication date: 2026/07/29
Liu QingqingYu PuLi XiaozhenLan HaiLiu Zenghui - Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by substantial genetic heterogeneity. Although routine molecular evaluation focuses on canonical driver alterations (, , , and ), additional somatic mutations have important diagnostic and prognostic implications. - Source: PubMed
Publication date: 2026/07/31
Tizro ParastouVail EricSapkota ManojGayhart Matthew GEno Celeste C - A new generation of molecular tests has revolutionized laboratory medicine through allowing for quick, sensitive, and precise identification of the pathogen; genetic mutation or alteration; and disease-related bio-markers. Of all the molecular techniques that exist today, PCR is still the most versatile, and clinically applicable technique available. This paper reviews the development of PCR technology from traditional amplification to advanced platforms including qPCR, dPCR, RT-PCR, and multiplex PCR. Each of the advanced platforms reviewed will be examined for their contributions to both the accurate detection, and quantification of nucleic acids along with the ability to perform high throughput analyses. Additionally, this paper also discusses how PCR technology can be integrated with additional technologies such as NGS, CRISPR-based diagnostic systems, microarrays, and epigenetic profiling to provide a larger view of disease states than was previously possible. Specifically, the focus of this paper will include many clinically relevant biomarkers and molecular targets used in cancer research including EGFR, KRAS, BRAF, BCR-ABL1, circulating tumor DNA (ctDNA), and methylated SEPT9. These biomarkers and molecular targets have greatly enhanced early diagnosis, prognostication, treatment monitoring and precision medicine in cancer research and other areas. The use of PCR-based technologies in diagnosing infectious diseases, tracking AMR, detecting heritable disorders, studying microbial communities, and MRD monitoring were also discussed. Further discussion included current trends in integrating multiple omics data types into a single platform using AI assisted data analysis tools. Liquid biopsy technologies and point-of-care molecular test platforms were also discussed. Although there are continuing challenges related to costs associated with developing these technologies, establishing standardized protocols for each technology type developed, having skilled technicians develop and validate these technologies, and managing large amounts of data generated when using these technologies; continued advances are providing greater access to these technologies to clinicians and ultimately patients. - Source: PubMed
Publication date: 2026/08/12
Saleem Muhammad AliRiaz TaimoorSaleem FatimaZeshan MuhammadRasul IjazZubair Muhammad - Tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 fusion protein have revolutionized the treatment of chronic myeloid leukemia (CML), transforming it into a chronic and manageable disease with markedly improved survival. However, prolonged TKI exposure has been associated with rare hematological complications, including secondary lymphoid malignancies. - Source: PubMed
Publication date: 2026/03/31
Mlayah ZainebMrad KmarBen Rekaya InèsBizid InaamSlama NaderLaatiri Mohamed AdnèneBoukhris Sarra